According to the recent study published in the Journal of American Medical Association, a new topical treatment for atopic dermatitis (AD) has been shown as a safe, effective, and ...

(RTTNews) - Arcutis Biotherapeutics Inc.'s (ARQT) ZORYVE cream 0.15% provided consistent and meaningful improvements in signs and symptoms of atopic dermatitis in individuals regardless of race, ...

ZORYVE demonstrated consistent efficacy in disease clearance and reduction in itch for individuals with atopic dermatitis (AD) regardless of race, ethnicity, and Fitzpatrick skin typeZORYVE was safe ...

WESTLAKE VILLAGE, Calif. - 美国食品和药物管理局（FDA）已接受Arcutis Biotherapeutics, Inc.（NASDAQ:ARQT）提交的ZORYVE（roflumilast）泡沫剂补充新药申请（sNDA），该药物用于治疗头皮和身体银屑病。FDA已将处方药用户费法案（PDUFA）目标行动日期定为2025年5月22日。 Arcutis是一家处于商业化阶段的生 ...